Spectral AI Inc. will exhibit its DeepView predictive‑diagnostic system at Booth 601 during the American Burn Association’s 2026 Annual Meeting, scheduled for April 14‑17 in Orlando, Florida. The conference will draw more than 2,200 burn‑care clinicians, researchers and leaders, giving Spectral AI a high‑profile platform to demonstrate the device’s ability to provide immediate, objective healing predictions for burn wounds.
DeepView uses multispectral imaging combined with an AI algorithm to forecast wound healing trajectories. The ABA showcase is a key step toward the company’s anticipated FDA De Novo clearance later in 2026, a regulatory milestone that will unlock broader clinical adoption and potential commercial sales in the United States.
Spectral AI’s progress is underpinned by substantial BARDA support, including a $31.7 million award in March 2026 that accelerates DeepView’s development. The company’s 2026 revenue guidance of approximately $18.5 million reflects BARDA contract revenue and explicitly excludes material sales of the DeepView system, indicating that commercial revenue is not yet expected for the year.
The event will allow Spectral AI to strengthen relationships with burn‑center stakeholders, gather real‑world feedback, and accelerate market entry once regulatory approval is obtained. The company’s financial trajectory has improved, with net income rising to $0.6 million in Q4 2025 from a $7.7 million loss in Q4 2024, underscoring a stronger financial position as it moves toward commercialization.
The announcement underscores Spectral AI’s advancement toward FDA clearance and positions the company to capitalize on growing demand for AI‑driven wound‑care solutions, marking a significant milestone in its commercialization strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.